Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing.MONROVIA, Calif. -- Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, announced today that Bassil Dahiyat, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will participate on a panel entitled "Antibody Therapeutics on the Rise: Future Antibody Technologies" during the BIO InvestorForum in San Francisco on Wednesday, October 19 at 9:10 a.m. Dr. Dahiyat will discuss novel approaches to improving the design of antibody therapeutics, including the use of Xencor's proprietary Protein Design Automation(R) platform. The panel will be moderated by Jason Kantor, Ph.D., Managing Director and Biotechnology Equity Research Analyst, RBC Capital Markets RBC Capital Markets is the corporate and investment banking division of Royal Bank of Canada ("RBC"). Broker dealers Depending on the jurisdiction, the division uses different broker dealer subsidiaries of RBC:
The act of raising money for company activities by selling common or preferred stock to individual or institutional investors. In return for the money paid, shareholders receive ownership interests in the corporation. , Wednesday at 4:40 p.m. The financing, led by Zen Investments, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control ., of Chicago, will fund the initiation of a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I of Xencor's proprietary protein therapeutic for the treatment of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , XPro(TM)1595, as well as ongoing development of the company's pipeline of XmAb(TM) antibody therapeutics. To date, Xencor has raised more than $85 million to create multiple antibody and protein drug candidates based on its Protein Design Automation technology platform. In addition to advancing its lead protein therapeutic drug candidate to the clinic, Xencor has licensed protein therapeutic candidates to partner Eli Lilly & Company. Xencor is also developing numerous therapeutic antibodies with improved effector effector /ef·fec·tor/ (e-fek´ter) 1. an agent that mediates a specific effect. 2. an organ that produces an effect in response to nerve stimulation. functions for internal advancement and for major partners including Genentech and Centocor. "With the Protein Design Automation technology platform, Xencor has successfully engineered antibodies and proteins with improved potency, stability and selectivity for our own development and for our partners," said Bassil Dahiyat, president and CEO of Xencor. "This financing round will enable the company to advance into the clinic our novel ligand and target receptor-specific inhibitor of tumor necrosis factor tumor necrosis factor n. Abbr. TNF A protein that is produced in the presence of an endotoxin, especially by monocytes and macrophages, is able to attack and destroy tumor cells, and exacerbates chronic inflammatory diseases. , XPro1595, and to continue preclinical development of our broad pipeline of antibody therapeutics." About Protein Design Automation Technology PDA (Personal Digital Assistant) A handheld computer for managing contacts, appointments and tasks. It typically includes a name and address database, calendar, to-do list and note taker, which are the functions in a personal information manager (see PIM). technology combines high performance computing with proprietary molecular biology processes and assays to create very broad protein diversity with exquisite control and efficiency. This technology takes advantage of the information embedded in protein structure to optimize key protein properties, such as binding affinity, selectivity, stability and expression level, which are targeted to yield therapeutic proteins with enhanced safety and efficacy in the clinic. The application of PDA technology creates new intellectual property, continually broadening Xencor's patent portfolio by generating sets of novel protein sequences that are distinct from naturally occurring proteins. About Xencor Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation(R) technology platform. The company is internally advancing both XPro(TM) protein therapeutic candidates and XmAb(TM) antibody drug candidates optimized for activity against biologically validated targets. Xencor's product development is lead by a protein therapeutic drug candidate, XPro1595, for the treatment of arthritis and other rheumatic rheu·mat·ic adj. Relating to or characterized by rheumatism. n. One who is affected by rheumatism. rheumatic pertaining to or affected with rheumatism. disorders and antibody candidates for the treatment of cancer. With multiple partners such as industry leaders Genentech and Roche, Xencor is applying its suite of XmAb antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. Xencor also develops therapeutic protein variants in collaboration with major pharmaceutical partners. For more information, please visit www.xencor.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion